Unibest

Pharmaceutical intermediates

Ritlecitinib Intermediates

2 pharmaceutical intermediates for Ritlecitinib. Indication: Alopecia Areata.

提交项目All intermediates

About Ritlecitinib

Originator
Pfizer Inc
Indication
Alopecia Areata
Approved Date
06/23/2023
NCE Patent
06/23/2028
DS/DP
12/03/2034

Available intermediates

2 intermediates currently listed for Ritlecitinib. Request specifications, documentation or a quotation for any item below.

Ritlecitinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
benzyl (2S,5R)-5-amino-2-methylpiperidine-1-carboxylate hydrochloride1207853-23-3//
2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine90213-66-4//

Other programs under R

Ramelteon RegorafenibRelugolixRemdesivir RemibrutinibRepotrectinibResmetiromRevumenib

Building toward Ritlecitinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →